Patents by Inventor Thomas Arrhenius

Thomas Arrhenius has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
    Patent number: 8119819
    Abstract: The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: February 21, 2012
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Thomas Arrhenius, Mi Chen, Jie Fei Cheng, Yujin Huang, Alex Michael Nadzan, Richard Julius Penuliar, David Mark Wallace, Lin Zhang, Gary D. Lopaschuk, Jason R. Dyck
  • Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
    Patent number: 8110686
    Abstract: The present invention relates to methods of treatment of certain metabolic diseases, and to novel compounds and their prodrugs, and/or pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds useful in treating such diseases. In particular, this invention relates to the use of novel compounds and compositions for treatment of cardiovascular diseases, diabetes, cancers, acidosis, and obesity through the inhibition of malonyl-CoA decarboxylase (MCD). These compounds have the formulae (I) and (II), wherein Y, C, R1, R2, R6, and R7 are defined herein.
    Type: Grant
    Filed: May 3, 2010
    Date of Patent: February 7, 2012
    Assignee: Chugai Seiyaki Kabushiki Kaisha
    Inventors: Thomas Arrhenius, Jie Fei Cheng, Mark E. Wilson, Rossy Serafimov, Alex M. Nadzan, Gary D. Lopaschuk, Jason R. Dyck
  • Piperidine compounds useful as malonyl-CoA decarboxylase inhibitors
    Patent number: 8080665
    Abstract: The present invention provides methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. The compounds disclosed in this invention are useful for the prophylaxis, management and treatment of diseases involving in malonyl-CoA regulated glucose/fatty acid metabolism pathway. In particular, these compounds and pharmaceutical composition containing the same are indicated in the prophylaxis, management and treatment of cardiovascular diseases, diabetes, cancer and obesity.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: December 20, 2011
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Jie Fei Cheng, Mi Chen, Thomas Arrhenius, Mark E. Wilson, Gary D. Lopaschuk, Jason R. Dyck, Rossy Serafimov
  • Coumarin derivatives useful as TNF? inhibitors
    Patent number: 7994318
    Abstract: Novel compounds composition capable of inhibiting TNF? and having antiimmunionflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: August 9, 2011
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Jie Fei Cheng, Thomas Arrhenius, David Wallace, Mi Chen, Sovouthy Tith, Hirotaka Kashiwagi, Yoshiyuki Ono, Yoshiaki Watanabe
  • Azoles as Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators
    Publication number: 20110028514
    Abstract: The present invention relates to methods of treatment of certain metabolic diseases, and to novel compounds and their prodrugs, and/or pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds useful in treating such diseases. In particular, this invention relates to the use of novel compounds and compositions for treatment of cardiovascular diseases, diabetes, cancers, acidosis, and obesity through the inhibition of malonyl-CoA decarboxylase (MCD). These compounds have the formulae (I) and (II), wherein Y, C, R1, R2, R6, and R7 are defined herein.
    Type: Application
    Filed: May 3, 2010
    Publication date: February 3, 2011
    Inventors: Thomas Arrhenius, Jie Fei Cheng, Mark E. Wilson, Rossy Serafimov, Alex M. Nadzan, Gary D. Lopaschuk, Jason R. Dyck
  • Coumarin derivatives useful as TNF? inhibitors
    Patent number: 7872142
    Abstract: Novel compounds composition capable of inhibiting TNF? and having antiimmunoinflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: January 18, 2011
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Jie Fei Cheng, Thomas Arrhenius, David Wallace, Mi Chen, Sovouthy Tith, Hirotaka Kashiwagi, Yoshiyuki Ono, Yoshiaki Watanabe
  • Cyanoguanidine-based azole compounds useful as malonyl-CoA decarboxylase inhibitors
    Patent number: 7786145
    Abstract: The present invention provides methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. The compounds disclosed in this invention are useful for the prophylaxis, management and treatment of diseases involving in malonyl-CoA regulated glucose/fatty acid metabolism pathway. In particular, these compounds and pharmaceutical composition containing the same are indicated in the prophylaxis, management and treatment of cardiovascular diseases, diabetes, cancer and obesity.
    Type: Grant
    Filed: July 28, 2004
    Date of Patent: August 31, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Jie Fei Cheng, Bin Liu, Thomas Arrhenius, Mark E. Wilson, Alex M. Nadzan, Gary D. Lopaschuk, Jason R. Dyck, Rossy Serafimov
  • COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS
    Publication number: 20100197917
    Abstract: Novel compounds composition capable of inhibiting TNF? and having antiimmunionflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.
    Type: Application
    Filed: March 18, 2010
    Publication date: August 5, 2010
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Jie Fei Cheng, Thomas Arrhenius, David Wallace, Mi Chen, Sovouthy Tith, Hirotaka Kashiwagi, Yoshiyuki Ono, Yoshiaki Watanabe
  • COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS
    Publication number: 20100174076
    Abstract: Novel compounds composition capable of inhibiting TNF? and having antiimmunionflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.
    Type: Application
    Filed: March 18, 2010
    Publication date: July 8, 2010
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Jie Fei Cheng, Thomas Arrhenius, David Wallace, Mi Chen, Sovouthy Tith, Hirotaka Kashiwagi, Yoshiyuki Ono, Yoshiaki Watanabe
  • Azole compounds as malonyl-CoA decarboxylase inhibitors for treating metabolic diseases
    Patent number: 7723366
    Abstract: The present invention relates to methods of treatment of certain metabolic diseases, and to the use of compounds and their prodrugs, and/or pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds useful in treating such diseases. In particular, the invention relates to the use of compounds and compositions for treatment of cardiovascular diseases, diabetes, cancers, acidosis, and obesity through the inhibition of malonyl-CoA decarboxylase (MCD). These compounds have the following formulae: (I) and (II) Wherein Y, C, R1, R2, R6, and R7 are defined herein.
    Type: Grant
    Filed: February 19, 2002
    Date of Patent: May 25, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Thomas Arrhenius, Jie Fei Cheng, Mark E. Wilson, Rossy Serafimov, Masahiro Nishimoto, David Mark Wallace, Sovouthy Tith, Steve Joel Brown, Charles Stanford Harmon, Gary D. Lopaschuk, Jason R. Dyck
  • Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
    Patent number: 7709510
    Abstract: The present invention relates to methods of treatment of certain metabolic diseases, and to novel compounds and their prodrugs, and/or pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds useful in treating such diseases. In particular, this invention relates to the use of novel compounds and compositions for treatment of cardiovascular diseases, diabetes, cancers, acidosis, and obesity through the inhibition of malonyl-CoA decarboxylase (MCD). These compounds have the formulae (I) and (II), wherein Y, C, R1, R2, R6, and R7 are defined herein.
    Type: Grant
    Filed: February 19, 2002
    Date of Patent: May 4, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Thomas Arrhenius, Jie Fei Cheng, Mark E. Wilson, Rossy Serafimov, Alex M. Nadzan, Gary D. Lopaschuk, Jason R. Dyck
  • Coumarin derivatives useful as TNF? inhibitors
    Patent number: 7709664
    Abstract: Novel compounds composition capable of inhibiting TNF? and having anti immunoinflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.
    Type: Grant
    Filed: September 13, 2005
    Date of Patent: May 4, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Jie Fei Cheng, Thomas Arrhenius, David Wallace, Mi Chen, Sovouthy Tith, Hirotaka Kashiwagi, Yoshiyuki Ono, Yoshiaki Watanabe
  • Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators
    Publication number: 20100016259
    Abstract: The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.
    Type: Application
    Filed: April 28, 2009
    Publication date: January 21, 2010
    Inventors: Thomas Arrhenius, Mi Chen, Jie Fei Cheng, Yujin Huang, Alex Michael Nadzan, Richard Julius Penuliar, David Mark Wallace, Lin Zhang, Gary D. Lopaschuk, Jason R. Dyck
  • Piperidine Compounds Useful as Malonyl-CoA Decarboxylase Inhibitors
    Publication number: 20090124660
    Abstract: The present invention provides methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. The compounds disclosed in this invention are useful for the prophylaxis, management and treatment of diseases involving in malonyl-CoA regulated glucose/fatty acid metabolism pathway. In particular, these compounds and pharmaceutical composition containing the same are indicated in the prophylaxis, management and treatment of cardiovascular diseases, diabetes, cancer and obesity.
    Type: Application
    Filed: October 3, 2008
    Publication date: May 14, 2009
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Jie Fei Cheng, Mi Chen, Thomas Arrhenius, Mark E. Wilson, Gary D. Lopaschuk, Jason R. Dyck, Rossy Serafimov
  • Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
    Patent number: 7524969
    Abstract: The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: April 28, 2009
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Thomas Arrhenius, Mi Chen, Jie Fei Chang, Yujin Huang, Alex Michael Nadzan, Richard Julius Penuliar, David Mark Wallace, Lin Zhang, Gary D. Lopaschuk, Jason R. Dyck
  • Piperidine compounds useful as malonyl-CoA decarboxylase inhibitors
    Patent number: 7449482
    Abstract: The present invention provides methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. The compounds disclosed in this invention are useful for the prophylaxis, management and treatment of diseases involving in malonyl-CoA regulated glucose/fatty acid metabolism pathway. In particular, these compounds and pharmaceutical composition containing the same are indicated in the prophylaxis, management and treatment of cardiovascular diseases, diabetes, cancer and obesity.
    Type: Grant
    Filed: July 28, 2004
    Date of Patent: November 11, 2008
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Jie Fei Cheng, Mi Chen, Thomas Arrhenius, Mark E. Wilson, Gary D. Lopaschuk, Jason R. Dyck, Rossy Serafimov
  • Method for preparing imidazole derivatives
    Patent number: 7385063
    Abstract: The present invention relates to methods for the prophylaxis, management and treatment of certain diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD) by the administration of a composition containing as an active ingredient a compound according to Formula I. In particular, the invention relates to methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the administration of a compound which inhibits malonyl-coenzyme A decarboxylase activity.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: June 10, 2008
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Thomas Arrhenius, Mi Chen, Jie Fei Cheng, Yujin Huang, Alex Michael Nadzan, Sovouthy Tith, Masayuki Haramura, David Mark Wallace, Steve Joel Brown, Charles Stanford Harmon, Lin Zhang, Gary D. Lopaschuk, Jason R. Dyck
  • Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators
    Publication number: 20080070869
    Abstract: The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.
    Type: Application
    Filed: September 14, 2007
    Publication date: March 20, 2008
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Thomas Arrhenius, Mi Chen, Jie Fei Cheng, Yujin Huang, Alex Nadzan, Sovouthy Tith, David Wallace, Bin Liu, Masahiro Nishimoto, Gary Lopaschuk, Jason Dyck
  • Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
    Patent number: 7279477
    Abstract: The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: October 9, 2007
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Thomas Arrhenius, Mi Chen, Jie Fei Cheng, Yujin Huang, Alex Michael Nadzan, Sovouthy Tith, David Mark Wallace, Bin Liu, Masahiro Nishimoto, Gary D. Lopaschuk, Jason R. Dyck
  • Coumarin derivatives useful as TNF? inhibitors
    Patent number: 7026491
    Abstract: Novel compounds composition capable of inhibiting TNF? and having antiimmunoinflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: April 11, 2006
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Jie Fei Cheng, Hirotaka Kashiwagi, Thomas Arrhenius, David Wallace, Mi Chen, Sovouthy Tith, Yoshiyuki Ono, Yoshiaki Watanabe